Fiche société
Eli Lilly and Company
Traitements, essais et publications liés.
Traitements25programmes
Essais23liés
Publications3liées
SourceDBlocale
Traitements
25| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ClazakizumabThe purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months. | Hypertension | Phase 2 | Immunomodulation | United States, Argentina, Japan, Puerto Rico | À vérifier |
| GalcanezumabThe main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine. | Migraine | Phase 3 | À vérifier | United States, Denmark, Germany, India, Italy, Japan, Mexico, Netherlands, … | À vérifier |
| LY2216684The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme. Because LY2216684 has been observed to increase heart rate in some healthy participants, this study will also assess heart rate when coadministered with theophylline. | SEP | Phase 1 | À vérifier | United States | À vérifier |
| LY3295668 ErbumineThe reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma. | Épilepsie | Phase 1 | À vérifier | United States, Australia, Belgium, France, Germany, Italy, Japan, Spain, … | À vérifier |
| LY3439539The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month. | Alzheimer | Phase 1 | À vérifier | United States, Australia, New Zealand, Singapore | À vérifier |
| LY4256984Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | Belgium, Canada, Germany, Netherlands, Spain | À vérifier |
| LY4298445The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks. | Lupus | Phase 1 | À vérifier | Australia, China | À vérifier |
| LY4405094The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU. | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| SolanezumabThe purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \[AD\]). | Alzheimer | Phase 3 | Ralentissement de la progression | United States, Australia, Canada, Japan | À vérifier |
| GalcanezumabThe main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine. | Migraine | Phase 3 | À vérifier | United States, Argentina, Canada, Czechia, Germany, Israel, Italy, Mexico, Netherlands, Puerto Rico, Spain, Taiwan, United Kingdom | À vérifier |
| LY3439539The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month. | Alzheimer | Phase 1 | À vérifier | United States, Australia, New Zealand, Singapore | À vérifier |
| GalcanezumabThe main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine. | Migraine | À vérifier | À vérifier | United States | À vérifier |
| GalcanezumabThe main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine. | Migraine | Phase 3 | À vérifier | United States, Denmark, Germany, India, Italy, Japan, Mexico, Netherlands, Puerto Rico, Spain | À vérifier |
| LY4256984Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | Belgium, Canada, Germany, Netherlands, Spain | À vérifier |
| LY4256984Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | Belgium, Canada, Germany, Netherlands, Spain | À vérifier |
| SolanezumabThe purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \[AD\]). | Alzheimer | Phase 3 | Ralentissement de la progression | United States, Australia, Canada, Japan | À vérifier |
| GalcanezumabThe main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine. | Migraine | Phase 3 | À vérifier | United States, Denmark, France, Germany, India, Italy, Japan, Mexico, Netherlands, Puerto Rico, Spain | À vérifier |
| GalcanezumabThe main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine. | Migraine | Phase 4 | À vérifier | United States | À vérifier |
| GalcanezumabThe main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine. | Migraine | Phase 3 | À vérifier | China, India, Russia | À vérifier |
| LY4405094The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU. | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| LY4405094The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU. | Alzheimer | Phase 1 | À vérifier | United States | À vérifier |
| LY3295668 ErbumineThe reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma. | Épilepsie | Phase 1 | À vérifier | United States, Australia, Belgium, France, Germany, Italy, Japan, Spain, United Kingdom | À vérifier |
| ClazakizumabThe purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months. | Hypertension | Phase 2 | Immunomodulation | United States, Argentina, Japan, Puerto Rico | À vérifier |
| LY4298445The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks. | Lupus | Phase 1 | À vérifier | Australia, China | À vérifier |
| LY2216684The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme. Because LY2216684 has been observed to increase heart rate in some healthy participants, this study will also assess heart rate when coadministered with theophylline. | SEP | Phase 1 | À vérifier | United States | À vérifier |
Essais cliniques
23| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| LY2216684 | SEP | Phase 1 | NCT01263106 | A Study of LY2216684 and Theophylline in Healthy Subjects | COMPLETED |
| LY4298445 | Lupus | Phase 1 | NCT07276958 | A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) | RECRUITING |
| Lasmiditan | Migraine | Phase 3 | NCT04396236 | PIONEER-PEDS1 — A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Clazakizumab | Hypertension | Phase 2 | NCT07783802 | CLARITY-CRP — A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | NOT_YET_RECRUITING |
| LY3295668 Erbumine | Épilepsie | Phase 1 | NCT04106219 | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | ACTIVE_NOT_RECRUITING |
| LY4405094 | Alzheimer | Phase 1 | NCT07787169 | A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease | NOT_YET_RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| LY4405094 | Alzheimer | Phase 1 | NCT07787182 | A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease | NOT_YET_RECRUITING |
| Lasmiditan | Migraine | Phase 2 | NCT03962738 | MONONOFU — A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine | COMPLETED |
| Galcanezumab | Migraine | Phase 3 | NCT03963232 | PERSIST — A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine | COMPLETED |
| Galcanezumab | Migraine | Phase 4 | NCT05127486 | CHALLENGE-MIG — A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine | COMPLETED |
| Galcanezumab | Migraine | Phase 3 | NCT04616326 | REBUILD-2 — A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine | ACTIVE_NOT_RECRUITING |
| Lasmiditan | Migraine | Phase 3 | NCT04396574 | PIONEER-PEDS2 — A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Solanezumab | Alzheimer | Phase 3 | NCT02008357 | A4 — Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss | COMPLETED |
| LY4256984 | Sclérose latérale amyotrophique | Phase 1 | NCT07571200 | A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) | RECRUITING |
| Donanemab | Alzheimer | Phase 2 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT07571161 | Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease | RECRUITING |
| LY4256984 | Sclérose latérale amyotrophique | Phase 1 | NCT07571174 | A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | RECRUITING |
| Galcanezumab | Migraine | Phase 3 | NCT03432286 | REBUILD-1 — A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| Galcanezumab | Migraine | À vérifier | NCT06085144 | Emgality for Migraine in Breastmilk | RECRUITING |
| LY3439539 | Alzheimer | Phase 1 | NCT07598370 | A Study of LY3439539 in Participants With Alzheimer's Disease | RECRUITING |
| Galcanezumab | Migraine | Phase 3 | NCT02614261 | REGAIN — Evaluation of Galcanezumab in the Prevention of Chronic Migraine | COMPLETED |
| Lasmiditan | Migraine | Phase 2 | NCT00883051 | Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment | COMPLETED |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Galcanezumab | Case Report: Anodal DLPFC-tDCS for refractory post-traumatic cognitive fatigue in the hypometabolic brain. | Frontiers in human neuroscience | ||
| Galcanezumab | CGRP-pathway exposure during the pre-EBP interval in spontaneous intracranial hypotension: an exploratory retrospective case series. | BMC neurology | ||
| Galcanezumab | Comparing synthetic and biological therapy for the treatment of cluster headache: what is needed and when? | Expert review of neurotherapeutics |